Clinical Trials
6 trialsNCT06120972 2025-02-12
Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency
University of Pittsburgh
Phase 2 Withdrawn
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT05295589 2023-09-26
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT04239014 2021-03-10
DUETTE
AstraZeneca
Phase 2 Withdrawn
NCT02392676 2016-05-02
Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations
AstraZeneca
Phase 3 Withdrawn
NCT01661868 2012-08-21
Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer
Dana-Farber Cancer Institute
Phase 2 Withdrawn